SavedAdd your journal

Journals / Turkish Journal of Medical Sciences / 2018 / Cilt: 48 - Sayı: 5

Paricalcitol inhibits the Wnt/beta-catenin signaling pathway and ameliorates experimentally induced arthritis

Ahmet TEKTEMUR
Zulfinaz Betül ÇELİK
Süleyman Serdar KOCA
Mehmet Mustafa AKIN
İbrahim Hanifi ÖZERCAN
Ebru ÖNALAN ETEM
Ahmet YILDIRIM
Servet YOLBAŞ
Pages
1080–1086
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Paricalcitol and the Wnt/β-catenin pathway are candidates for research in humanrheumatoid arthritis.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/aim: The Wnt/β-catenin pathway has important biological activities, including the differentiation of cells and jointformations.
📊
Key Findings & Data:The aim of our study was to determine the effect of paricalcitol on experimentally induced arthritis.Materials and methods: Type II collagen combined with Freund’s adjuvant was applied to induce arthritis in Wistar albino female rats.Paricalcitol (0.3 µg/kg daily) was subcutaneously injected starting 1 day after collagen applications (prophylactic group) or 1 day afterthe onset of arthritis (therapeutic group), until day 29.Results: The 29th day arthritis scores were lower compared to the 13th day scores in the paricalcitol groups (P < 0.05), while they werehigher in the arthritis group (P < 0.05).
💡
Conclusion & Impact:Paricalcitol and the Wnt/β-catenin pathway are candidates for research in humanrheumatoid arthritis.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background/aim: The Wnt/β-catenin pathway has important biological activities, including the differentiation of cells and jointformations. The aim of our study was to determine the effect of paricalcitol on experimentally induced arthritis.Materials and methods: Type II collagen combined with Freund’s adjuvant was applied to induce arthritis in Wistar albino female rats.Paricalcitol (0.3 µg/kg daily) was subcutaneously injected starting 1 day after collagen applications (prophylactic group) or 1 day afterthe onset of arthritis (therapeutic group), until day 29.Results: The 29th day arthritis scores were lower compared to the 13th day scores in the paricalcitol groups (P < 0.05), while they werehigher in the arthritis group (P < 0.05). Marked cartilage-bone destruction and extensive perisynovial inflammation were detected inthe arthritis group. Decreased cartilage-bone destruction and perisynovial inflammation in the paws were observed in the paricalcitolgroups. The tissue mRNA levels of DKK1, Wnt5a, and axin-2 were higher in the arthritis group than in the control group. In theparicalcitol groups, mRNA expressions were lower than in the arthritis group.Conclusion: The present study shows that the Wnt/β-catenin signaling pathway is active in arthritis. Moreover, paricalcitol amelioratesarthritis via inhibiting the Wnt/β-catenin pathway. Paricalcitol and the Wnt/β-catenin pathway are candidates for research in humanrheumatoid arthritis.

🔖

Cite This Article

TEKTEMUR, A., ÇELİK, Z. B., KOCA, S. S., AKIN, M. M., ÖZERCAN, İ. H., ETEM, E. Ö., YILDIRIM, A., YOLBAŞ, S. (2022). Paricalcitol inhibits the Wnt/beta-catenin signaling pathway and ameliorates experimentally induced arthritis. Turkish Journal of Medical Sciences, Cilt: 48 - Sayı: 5, 1080–1086. https://ajindex.com/articles/610198

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 2010; 376: 1094-1108.
  2. Nurmohamed MT, Dijkmans BA. Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis. Drugs 2005; 65: 661- 694. Salliot C, Finckh A, Katchamart W, Lu Y, Sun Y, Bombardier C, Keystone E. Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis. Ann Rheum Dis 2011; 70: 266-271.
  3. Mavers M, Ruderman EM, Perlman H. Intracellular signal pathways: potential for therapies. Curr Rheumatol Rep 2009; 11: 378-385. Rabelo Fde S, da Mota LM, Lima RA, Lima FA, Barra GB, de Carvalho JF, Amato AA. The Wnt signaling pathway and rheumatoid arthritis. Autoimmun Rev 2010; 9: 207-210.
  4. Shaw AT, Gravallese EM. Mediators of inflammation and bone remodeling in rheumatic disease. Semin Cell Dev Biol 2016; 49: 2-10.
  5. Van Amerongen R, Nusse R. Towards an integrated view of Wnt signaling in development. Development 2009; 136: 3205-3214.
  6. Sen M, Lauterbach K, El-Gabalawy H, Firestein GS, Corr M, Carson DA. Expression and function of wingless and frizzled homologs in rheumatoid arthritis. P Natl Acad Sci USA 2000; 97: 2791-2796.
  7. Nakamura Y, Nawata M, Wakitani S. Expression profiles and functional analyses of Wnt-related genes in human joint disorders. Am J Pathol 2005; 167: 97-105.
  8. Imai K, Morikawa M, D’Armiento J, Matsumoto H, Komiya K, Okada Y. Differential expression of WNTs and FRPs in thes ynovium of rheumatoid arthritis and osteoarthritis. Biochem Biophys Res Commun 2006; 345: 1615-1620.
  9. Sen M, Reifert J, Lauterbach K, Wolf V, Rubin JS, Corr M, Carson DA. Regulation of fibronectin and metalloproteinase expression by Wnt signaling in rheumatoid arthritis synoviocytes. Arthritis Rheum 2002; 46: 2867-2877.
  10. Notani D, Gottimukkala KP, Jayani RS, Limaye AS, Damle MV, Mehta S, Purbey PK, Joseph J, Galande S. Global regulator SATB1 recruits beta-catenin and regulates T(H)2 differentiation in Wnt-dependent manner. PLoS Biol 2010; 8: e1000296. Yu Q, Sharma A, Oh SY, Moon HG, Hossain MZ, Salay TM, Leeds KE, Du H, Wu B, Waterman ML et al. T cell factor 1 initiates the T helper type 2 fate by inducing the transcription factor GATA-3 and repressing interferon-gamma. Nat Immunol 2009; 10: 992-999.
  11. Ding Y, Shen S, Lino AC, Curotto de Lafaille MA, Lafaille J